{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-024496","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.966651+00:00","generated_at":"2026-06-15T00:59:59.958919+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PDS Biotech reports Q1 net loss of $9.7M; plans Phase 3 trial for PDS0101 in Q4 2023","bullets":["Q1 net loss $9.7M ($0.32/sh) vs $8.5M ($0.32/sh) in Q1 2022; R&D spend rose to $5.8M.","Cash $65.2M at March 31, 2023; expected to fund operations into Q3 2024.","VERSATILE-002 Phase 2 data to be presented at ASCO 2023; Phase 3 VERSATILE-003 initiation planned for Q4 2023.","Received $1.4M from sale of NJ tax benefits; NCI-led triple combination trial progressing.","Preclinical Infectimune data showing flu protection published in peer-reviewed journal."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-024496","json":"https://secwatch.observer/filing/0001140361-23-024496.json","markdown":"https://secwatch.observer/filing/0001140361-23-024496.md","text":"https://secwatch.observer/filing/0001140361-23-024496.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036123024496/0001140361-23-024496-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036123024496/brhc20052894_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T00:59:59.958919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c1a7a51c1f6771cea1518aa2d43319de97ec1742","claim":"PDS Biotechnology Corp reported the three months ended March 31, 2023 results: net income approximately $9.7 million, EPS $0.32 per basic share and diluted share.","evidence_excerpt":"Reported net loss was approximately $9.7 million, or $0.32 per basic share and diluted share, for the three months ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036123024496/0001140361-23-024496-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Net income","value":"approximately $9.7 million"},{"label":"EPS","value":"$0.32 per basic share and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}